<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00409201</url>
  </required_header>
  <id_info>
    <org_study_id>284</org_study_id>
    <nct_id>NCT00409201</nct_id>
  </id_info>
  <brief_title>Reboxetine Adjuvant Therapy for the Treatment of Schizophrenia</brief_title>
  <official_title>Phase 1 Study of Reboxetine Adjuvant Therapy and Cognitive and Behavioral Measures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abarbanel Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abarbanel Mental Health Center</source>
  <brief_summary>
    <textblock>
      30 patients will randomly be selected and will be administered either reboxetine or a
      placebo. changes in cognition and behavior will be assessed by computer tests and scales
      during a six week study period.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      all participants will be administered panss, sans, esrs, calgary, progesterom, sexual
      functioning scale, ham-a, covy, hamilton depression scale, and cgi and cgi improved rating on
      the first visit, as well as blood tests, ecg and weight. they will then be tested using a
      computer cognitive test (cogscan test) that lasts about 45 minutes. next, they will be given
      either a two week dose of placebo or treatment (2 mg * 2 daily for first week, then 4 mg.
      day, 2 mg. night for the second week). after two weeks they the dose is increased to 4 mg. *
      2 daily. at four weeks all tests are readministered, as well as at six weeks. the study is
      concluded at 6 weeks, following a readministration of tests. physical examination is also
      administered at the conclusion.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2006</start_date>
  <completion_date>November 2006</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sans, panss, hamilton, ham-a, calgary, physical examination, cogscan test</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>esrs, progesterom, sexual functioning, covy, cgi, cgi improved</measure>
  </secondary_outcome>
  <enrollment>30</enrollment>
  <condition>Schizophrenia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>reboxetine adjuvant therapy</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  schizophrenia all types

          -  18&gt;

        Exclusion Criteria:

          -  uti

          -  &gt;65

          -  non organic state

          -  no depression treatment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>stanislav baranchik, md</last_name>
    <role>Principal Investigator</role>
    <affiliation>abarbanel mhc</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>stanislav baranchik, md</last_name>
    <phone>972-3-5552625</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Abarbanel Medical Mental Health Center</name>
      <address>
        <city>Bat Yam</city>
        <zip>59100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>stanislav baranchik, md</last_name>
      <phone>972-3-5552625</phone>
    </contact>
    <contact_backup>
      <last_name>alex aviv, md</last_name>
      <phone>972-3-552703</phone>
      <email>alexaviv@gmail.com</email>
    </contact_backup>
    <investigator>
      <last_name>stanislav baranchik, md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Abarbanel Medical Mental Health Center</name>
      <address>
        <city>Bat Yam</city>
        <zip>59100</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>stanislav baranchik, md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <reference>
    <citation>Schutz G, Berk M. Reboxetine add on therapy to haloperidol in the treatment of schizophrenia: a preliminary double-blind randomized placebo-controlled study. Int Clin Psychopharmacol. 2001 Sep;16(5):275-8.</citation>
    <PMID>11552770</PMID>
  </reference>
  <verification_date>March 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 7, 2006</study_first_submitted>
  <study_first_submitted_qc>December 7, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 8, 2006</study_first_posted>
  <last_update_submitted>December 7, 2006</last_update_submitted>
  <last_update_submitted_qc>December 7, 2006</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 8, 2006</last_update_posted>
  <keyword>schizophrenia</keyword>
  <keyword>reboxetine</keyword>
  <keyword>cognitive</keyword>
  <keyword>behavior</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Reboxetine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

